UNITY BIOTECHNOLOGY INC (UBX)

US91381U2006 - Common Stock

1.64  +0.01 (+0.61%)

After market: 1.58 -0.06 (-3.66%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

UNITY BIOTECHNOLOGY INC

NASDAQ:UBX (3/28/2024, 8:00:02 PM)

After market: 1.58 -0.06 (-3.66%)

1.64

+0.01 (+0.61%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap27.52M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

UBX Daily chart

Company Profile

Unity Biotechnology, Inc. operates as a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 32 full-time employees. The company went IPO on 2018-05-03. The firm is focused on creating medicines to selectively eliminate or modulate senescent cells. The firm is also focused on advancing senolytic programs primarily in ophthalmologic disorders. The company is also focused on advancing other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/vascular endothelial growth factor (VEGF) bispecific to treat vascular eye disease. The firm's UBX1325 and UBX1967 are designed to inhibit the function of proteins that senescent cells rely on for survival. UBX1325 is an advanced drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration, (AMD), and diabetic retinopathy (DR). Its UBX2050 is an investigational, fully human anti-Tie2 agonist monoclonal antibody.

Company Info

UNITY BIOTECHNOLOGY INC

285 East Grand Avenue

South San Francisco CALIFORNIA

P: 16504161192

Employees: 32

Website: https://unitybiotechnology.com/

UBX News

News Image2 months ago - Unity Biotechnology, Inc.New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
News Image2 months ago - Unity Biotechnology, Inc.New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing...

News Image3 months ago - Yahoo Finance10 Supplements for Longevity and Antiaging: Expert Recommendations

In this article, we are going to discuss the 10 Supplements for Longevity and Antiaging: Expert Recommendations. You can skip our detailed analysis and go directly to 5 Supplements for Longevity and Antiaging: Expert Recommendations. The anti-aging and longevity market is undergoing a fascinating transformation, driven by personalized approaches, cutting-edge science, and a growing emphasis on evidence-based […]

News Image4 months ago - Unity Biotechnology, Inc.UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME

Topline 16-week data expected in the fourth quarter of 2024

News Image4 months ago - Seeking AlphaUnity Biotechnology files to sell 2.27M shares of common stock for holders (NASDAQ:UBX)

Unity Biotechnology has filed a prospectus for the resale of up to 2,271,580 shares of common stock. This is not an offer to sell.

News Image4 months ago - Seeking AlphaWedbush upgrades Unity Biotechnology to outperform, cites cash runway (NASDAQ:UBX)

Wedbush upgrades Unity Biotechnology (UBX) to outperform, citing extension of the company's cash runway. Read more here.

UBX Twits

Here you can normally see the latest stock twits on UBX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example